Compound Detail
CHEMBL231779
APIXABAN 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL231779 |
| Name | APIXABAN |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | QNZCBYKSOIHPEH-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
8
Targets
31
Activities
3
Assay Types
30
PK Parameters
20
Publications
5
Known Names
20
Indications
1
Mechanisms
Molecular Properties
459.5
MW (Da)
2.70
ALogP
6
HBA
1
HBD
110.8
PSA (Ų)
0.63
QED
0
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2011 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Coagulation factor X inhibitor | INHIBITOR | Coagulation factor X | ✓ | ✓ |
Indications
Arthroplasty Atrial Fibrillation Embolism Pulmonary Embolism Stroke Thrombosis Thrombosis Venous Thromboembolism Venous Thrombosis Venous Thrombosis Acute Coronary Syndrome Anemia, Sickle Cell Aortic Valve Stenosis Atrial Flutter Hematoma Ischemia Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma Renal Insufficiency Severe Acute Respiratory Syndrome
ATC Classification
B01AF02
apixaban
Level 1: BLOOD AND BLOOD FORMING ORGANS
Level 2: ANTITHROMBOTIC AGENTS
Drug Warnings
Black Box Warning
vascular toxicity
Activity Summary
IC50 15 meas. best 8.65
Ki 14 meas. best 10.1
EC50 2 meas. best 7.16
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Coagulation factor X CHEMBL244 | Ki | 10.1 | 10.1 | 0.1 | 9 |
| Coagulation factor X CHEMBL5062 | Ki | 9.77 | 9.77 | 0.2 | 1 |
| Coagulation factor X CHEMBL3755 | Ki | 8.89 | 8.205 | 1.3 | 2 |
| Coagulation factor X CHEMBL244 | IC50 | 8.65 | 7.3233 | 2.3 | 3 |
| Plasma CHEMBL613424 | IC50 | 7.47 | 6.813 | 33.7 | 10 |
| Unchecked CHEMBL612545 | EC50 | 7.16 | 7.16 | 70.0 | 1 |
| Oryctolagus cuniculus CHEMBL374 | EC50 | 6.49 | 6.49 | 325.0 | 1 |
| Oryctolagus cuniculus CHEMBL374 | IC50 | 6.48 | 6.48 | 329.0 | 1 |
| Prothrombin CHEMBL204 | Ki | 5.51 | 5.51 | 3100.0 | 2 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 5.23 | 5.23 | 5910.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 0.3333 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 0.3333 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 0.3333 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 0.3333 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 0.26 | L/Kg | Rattus norvegicus |
| CL | 0.018 | L/Kg | Pan troglodytes |
| CL | 0.3333 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 21.0 | % | Canis lupus familiaris |
| CL | 11.83 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 0.3333 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 20.0 | % | Rattus norvegicus |
| CL | 42.0 | % | Canis lupus familiaris |
| CL | 27.0 | % | Homo sapiens |
| F | 58.0 | % | Canis lupus familiaris |
| F | 58.0 | % | Canis lupus familiaris |
| F | 58.0 | % | Canis lupus familiaris |
| F | 50.0 | % | Canis lupus familiaris |
| F | 51.0 | % | Pan troglodytes |
| F | 58.0 | % | Canis lupus familiaris |
| F | 30.0 | % | Rattus norvegicus |
| F | 70.0 | % | Canis lupus familiaris |
| F | 50.0 | % | Homo sapiens |
| F | 49.0 | % | Homo sapiens |
| F | 70.0 | % | Canis lupus familiaris |
| F | 30.0 | % | Rattus norvegicus |
| Fu | 0.07 | - | Homo sapiens |
| T1/2 | 5.8 | hr | Canis lupus familiaris |
| T1/2 | 5.8 | hr | Canis lupus familiaris |
| T1/2 | 5.8 | hr | Canis lupus familiaris |
| T1/2 | 8.0 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 34010555 | 10.1021/acs.jmedchem.0c01720 | ADMET | 25 |
| 25978966 | 10.1016/j.bmcl.2015.04.057 | Plasma | 10 |
| 20503967 | 10.1021/jm100146h | ADMET | 10 |
| 23382458 | 10.1124/dmd.112.050260 | ADMET | 7 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 6 |
| 27663548 | 10.1016/j.bmc.2016.09.024 | NON-PROTEIN TARGET | 5 |
| 17914785 | 10.1021/jm070245n | Canis familiaris | 4 |
| 20503967 | 10.1021/jm100146h | Canis familiaris | 4 |
| 24951330 | 10.1016/j.bmcl.2014.05.101 | Canis familiaris | 4 |
| 28389110 | 10.1016/j.bmc.2017.03.055 | Plasma | 4 |
| 18424044 | 10.1016/j.bmcl.2008.03.092 | Canis familiaris | 4 |
| 20503967 | 10.1021/jm100146h | Pan troglodytes | 4 |
| 19046881 | 10.1016/j.bmcl.2008.11.049 | Canis familiaris | 4 |
| 36634753 | 10.1016/j.bmcl.2023.129127 | Rattus norvegicus | 4 |
| 28389110 | 10.1016/j.bmc.2017.03.055 | Coagulation factor X | 3 |
| 19046881 | 10.1016/j.bmcl.2008.11.049 | Plasma | 3 |
| - | 10.6019/CHEMBL4495564 | Replicase polyprotein 1ab | 3 |
| 20503967 | 10.1021/jm100146h | Oryctolagus cuniculus | 3 |
| 20503967 | 10.1021/jm100146h | Rattus norvegicus | 3 |
| 17914785 | 10.1021/jm070245n | ADMET | 2 |
Data from ChEMBL 36 via Core Engine